The logo for Revvity, featuring the word "revvity" in a lowercase, rounded, sans-serif font. The letters are black and have a slightly irregular, hand-drawn feel. The background of the slide is white with a large, abstract graphic on the right side consisting of overlapping, semi-transparent, rounded shapes in shades of yellow, orange, and purple, resembling a stylized flower or a cluster of cells.

revvity

# Vanadis<sup>®</sup> NIPT and beyond

The cfDNA screening solution for all  
laboratories

Tarja Ahola/Howard Cuckle  
6<sup>th</sup> Central & Eastern European Congress  
on Cell-Free DNA and Medical Practice,  
March 7–8, 2024

# Vanadis<sup>®</sup> NIPT

Rolling circle cfDNA system designed to remove the complexity of testing, making it accessible to more women, and more cost-effective for laboratories

**Vanadis Extract<sup>®</sup>**  
Cell-Free DNA Extraction Unit



**Vanadis Core<sup>®</sup>**  
Cell-Free DNA Analysis Unit



**Vanadis View<sup>®</sup>**  
Molecule Counting Unit



**LifeCycle<sup>™</sup>**  
Risk Calculation Software



# Vanadis<sup>®</sup> NIPT: designed for T21, T18 & T13 screening



## Unique

- Non-sequencing non-PCR technology which can be run by any laboratory
- Cost-effective solution to increase access to more women



## Easy


- Walk-away automation enabling scalable throughput
- Streamlined workflow from primary tube to result with minimum hands-on time




## Precise

- Designed for high precision measurement to minimize the no-call rate
- Optimized for >99% T21 detection rate in all samples, including those with low fetal fraction

# Aneuploidy diagnosis game-changers





**cfDNA tests/year=7-10 million**

**Births/year=140 million**

**Upper & upper-middle income=50 million**

Primary

Secondary/Contingent

None

NK



Created with mapchart.net

75%+

25-50%

<25%

NK




Created with mapchart.net ©



PART



**iatrogenic loss=1.0**  
**iatrogenic loss=0.5**  
**iatrogenic loss=0.1**  
**iatrogenic loss=0.05**



# BALANCE SHEET

**Non-current assets**  
Property, plant and equipment  
Intangible assets  
Subsidiaries  
Associates  
Investments  
Receivables

Note

GROUP

20...  
\$'000  
(restated)

3  
4  
5  
6  
7  
8  
9

50,161	45,421
116	2,256
—	—
22,251	7,344
1,933	5,352
737	12
579	994
75,777	61,379
27,790	61,805
122,857	112,489
1,027	852
30,360	20,907
—	196,057
—	257,4

# Marginal cost

Total \$  
cfDNA

minus

Total \$  
Combined



DS births  
cfDNA

minus

DS births  
Combined

# Menu

NT scan-----\$150

\*

PAPP-A &  $\beta$ -hCG-----\$50

\*

CVS & IPND-----\$1500

\*

cfDNA-----\$200-\$1200

\*

DS lifetime-----\$1000000

**Marginal (million)**

**\$6**

**\$5**

**\$4**

**\$3**

**\$2**

**\$1**

**\$0**

**\$200**

**\$400**

**\$600**


**\$800**

**\$1 000**

**\$1 200**

**cfDNA test**

**Primary cfDNA**



Marginal (million)

\$6

\$5

\$4

\$3

\$2

\$1

\$0

\$200

\$400

\$600

\$800

\$1 000


\$1 200

cfDNA test


Primary cfDNA

Lifetime

\$450



Marginal (million)




Retain NT scan

Primary cfDNA

Lifetime


\$300

cfDNA test





Marginal (million)



Retain NT scan


Primary cfDNA

\$910

Contingent

Lifetime

cfDNA test



**cfDNA**

**Invasive**



**Cost neutral or better**





## **Helsinki University Hospital**

*Helsinki - Finland*

**Howard Cuckle, Seppo Heinonen, Anna-Kaisa Anttonen and Vedran Stefanovic**  
**Cost of providing cell-free DNA screening for Down syndrome in Finland using different strategies**

J. Perinat. Med. 2022; 50(3): 233–243

# Vanadis<sup>®</sup> NIPT system

Primary cfDNA @10,000 per year

**€155/test**

Contingent cfDNA @ 30%

**€200/test**


Secondary or Contingent cfDNA @10-20%

**€245/test**

Combined @ 10,000 per year

**€75+ €25/test**

# Additional/pregnancy



# Infrastructure





**MISSING**

- **Screening programs**
- **Population based**
- **Demonstrably cost-effective**
- **Managed**
- **Monitored**

# Thank you!

Contact information:

Revvity: Inga Pukonen ([inga.pukonen@revvity.com](mailto:inga.pukonen@revvity.com))

HVD: Anastasia Stamatopoulou ([anastasia.stamatopoulou@hvd.gr](mailto:anastasia.stamatopoulou@hvd.gr))

revvity

